Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetes

Biochimica et Biophysica Acta - General Subjects

Volumn 1820, Issue 5, 2012, Pages 663-671

  Yamagishi, Sho Ichi ^a   Maeda, Sayaka ^a   Matsui, Takanori ^a   Ueda, Seiji ^a   Fukami, Kei ^a   Okuda, Seiya ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

AGE; Diabetic vascular complication; Oxidative stress; RAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; AMINOGUANIDINE; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; PIGMENT EPITHELIUM DERIVED FACTOR; PLACEBO; PYRIDOXAMINE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; THIOCTIC ACID; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

CELL DAMAGE; CELL INTERACTION; CELL LOSS; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; FIBROSING ALVEOLITIS; GLOMERULOSCLEROSIS; HUMAN; MEMBRANE PERMEABILITY; MESANGIUM CELL; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PERICYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; THROMBOSIS; UPREGULATION;

ANIMALS; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS; DISEASE PROGRESSION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; OXIDATIVE STRESS;

EID: 84859343649     PISSN: 03044165     EISSN: 18728006     Source Type: Journal    
DOI: 10.1016/j.bbagen.2011.03.014     Document Type: Review

References (126)

1. S. Yamagishi, and T. Imaizumi Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy Curr. Pharm. Des. 11 2005 2279 2299 (Pubitemid 40872698)
2. M. Brownlee Biochemistry and molecular cell biology of diabetic complications Nature 414 2001 813 820 (Pubitemid 34000785)
3. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group N. Engl. J. Med. 329 1993 977 986
4. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group Lancet 352 1998 837 853
5. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group N. Engl. J. Med. 342 2000 381 389
6. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study JAMA 290 2003 2159 2167
7. D.M. Nathan, J. Lachin, P. Cleary, T. Orchard, D.J. Brillon, J.Y. Backlund, D.H. O'Leary, and S. Genuth Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus N. Engl. J. Med. 348 2003 2294 2303 (Pubitemid 36638103)
8. D.M. Nathan, P.A. Cleary, J.Y. Backlund, S.M. Genuth, J.M. Lachin, T.J. Orchard, P. Raskin, and B. Zinman Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes N. Engl. J. Med. 353 2005 2643 2653 (Pubitemid 41817713)
9. R.R. Holman, S.K. Paul, M.A. Bethel, D.R. Matthews, and H.A. Neil 10-year follow-up of intensive glucose control in type 2 diabetes N. Engl. J. Med. 359 2008 1577 1589
10. M. Brownlee, A. Cerami, and H. Vlassara Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications N. Engl. J. Med. 318 1988 1315 1321
11. H. Vlassara, and M.R. Palace Diabetes and advanced glycation endproducts J. Intern. Med. 251 2002 87 101 (Pubitemid 34146691)
12. M. Takeuchi, and S. Yamagishi Involvement of toxic AGEs (TAGE) in the pathogenesis of diabetic vascular complications and Alzheimer's disease J. Alzheimers Dis. 16 2009 845 858
13. D.G. Dyer, J.A. Blackledge, S.R. Thorpe, and J.W. Baynes Formation of pentosidine during nonenzymatic browning of proteins by glucose. Identification glucose other carbohydrates as possible precursors pentosidine vivo J Biol Chem 266 1991 11654 11660 (Pubitemid 21906999)
14. D. Stern, S.D. Yan, S.F. Yan, and A.M. Schmidt Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings Adv. Drug Deliv. Rev. 54 2002 1615 1625 (Pubitemid 35346835)
15. A. Bierhaus, M.A. Hofmann, R. Ziegler, and P.P. Nawroth AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus: I. The AGE concept Cardiovasc. Res. 37 1998 586 600 (Pubitemid 28231153)
16. S. Yamagishi, K. Nakamura, T. Matsui, S. Ueda, K. Fukami, and S. Okuda Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications Expert Opin. Investig. Drugs 17 2008 983 996
17. S. Yamagishi, K. Nakamura, T. Matsui, Y. Noda, and T. Imaizumi Receptor for advanced glycation end products (RAGE): a novel therapeutic target for diabetic vascular complication Curr. Pharm. Des. 14 2008 487 495 (Pubitemid 351516853)
18. K. Takenaka, S. Yamagishi, T. Matsui, K. Nakamura, and T. Imaizumi Role of advanced glycation end products (AGEs) in thrombogenic abnormalities in diabetes Curr. Neurovasc. Res. 3 2006 73 77
19. S. Yamagishi, K. Nakamura, and T. Matsui Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-modulating activity for the treatment of cardiometabolic disorders Curr. Mol. Med. 7 2007 463 469 (Pubitemid 47244891)
20. R.N. Frank On the pathogenesis of diabetic retinopathy. A 1990 update Ophthalmology 98 1991 586 593
21. A.W. Stitt, Y.M. Li, T.A. Gardiner, R. Bucala, D.B. Archer, and H. Vlassara Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats Am. J. Pathol. 150 1997 523 531 (Pubitemid 27073782)
22. S. Yamagishi, S. Amano, Y. Inagaki, T. Okamoto, K. Koga, N. Sasaki, H. Yamamoto, M. Takeuchi, and Z. Makita Advanced glycation end products-induced apoptosis and overexpression of vascular endothelial growth factor in bovine retinal pericytes Biochem. Biophys. Res. Commun. 290 2002 973 978 (Pubitemid 34687457)
23. S. Yamagishi, Y. Inagaki, S. Amano, T. Okamoto, M. Takeuchi, and Z. Makita Pigment epithelium-derived factor protects cultured retinal pericytes from advanced glycation end product-induced injury through its antioxidative properties Biochem. Biophys. Res. Commun. 296 2002 877 882
24. S. Yamagishi, S. Amano, Y. Inagaki, T. Okamoto, M. Takeuchi, and Z. Makita Beraprost sodium, a prostaglandin I2 analogue, protects against advanced gycation end products-induced injury in cultured retinal pericytes Mol. Med. 8 2002 546 550 (Pubitemid 36332366)
25. L. Ottonello, M.P. Morone, P. Dapino, and F. Dallegri Tumor necrosis factor-alpha-induced oxidative burst in neutrophils adherent to fibronectin: effects of cyclic AMP-elevating agents Br. J. Haematol. 91 1995 566 570
26. L.P. Aiello, R.L. Avery, P.G. Arrigg, B.A. Keyt, H.D. Jampel, S.T. Shah, L.R. Pasquale, H. Thieme, M.A. Iwamoto, and J.E. Park Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders N. Engl. J. Med. 331 1994 1480 1487 (Pubitemid 24356306)
27. T. Murata, T. Ishibashi, A. Khalil, Y. Hata, H. Yoshikawa, and H. Inomata Vascular endothelial growth factor plays a role in hyperpermeability of diabetic retinal vessels Ophthalmic Res. 27 1995 48 52
28. S. Yamagishi, K. Nakamura, T. Matsui, Y. Inagaki, K. Takenaka, Y. Jinnouchi, Y. Yoshida, T. Matsuura, I. Narama, Y. Motomiya, M. Takeuchi, H. Inoue, A. Yoshimura, R. Bucala, and T. Imaizumi Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression J. Biol. Chem. 281 2006 20213 20220 (Pubitemid 44065796)
29. S. Anderson Role of local and systemic angiotensin in diabetic renal disease Kidney Int. Suppl. 63 1997 S107 S110
30. S. Yamagishi, S. Amano, Y. Inagaki, T. Okamoto, H. Inoue, M. Takeuchi, H. Choei, N. Sasaki, and S. Kikuchi Angiotensin II-type 1 receptor interaction upregulates vascular endothelial growth factor messenger RNA levels in retinal pericytes through intracellular reactive oxygen species generation Drugs Exp. Clin. Res. 29 2003 75 80 (Pubitemid 36975512)
31. S. Amano, S. Yamagishi, Y. Inagaki, and T. Okamoto Angiotensin II stimulates platelet-derived growth factor-B gene expression in cultured retinal pericytes through intracellular reactive oxygen species generation Int. J. Tissue React. 25 2003 51 55 (Pubitemid 37168314)
32. S. Yamagishi, M. Takeuchi, T. Matsui, K. Nakamura, T. Imaizumi, and H. Inoue Angiotensin II augments advanced glycation end product-induced pericyte apoptosis through RAGE overexpression FEBS Lett. 579 2005 4265 4270 (Pubitemid 41116350)
33. J. Tombran-Tink, and C.J. Barnstable PEDF: a multifaceted neurotrophic factor Nat. Rev. Neurosci. 4 2003 628 636 (Pubitemid 37280158)
34. S.P. Becerra Focus on molecules: pigment epithelium-derived factor (PEDF) Exp. Eye Res. 82 2006 739 740
35. E.T. Ek, C.R. Dass, and P.F. Choong PEDF: a potential molecular therapeutic target with multiple anti-cancer activities Trends Mol. Med. 12 2006 497 502 (Pubitemid 44468197)
36. R. Abe, Y. Fujita, and S. Yamagishi Angiogenesis and metastasis inhibitors for the treatment of malignant melanoma Mini Rev Med Chem 7 2007 649 661 (Pubitemid 47099184)
37. S. Yamagishi, T. Matsui, K. Nakamura, S. Ueda, Y. Noda, and T. Imaizumi Pigment epithelium-derived factor (PEDF): its potential therapeutic implication in diabetic vascular complications Curr. Drug Targets 9 2008 1025 1029
38. S. Yamagishi, K. Nakamura, K. Takenaka, T. Matsui, Y. Jinnouchi, and T. Imaizumi Pigment epithelium-derived factor (PEDF) promotes growth of pericytes through autocrine production of platelet-derived growth factor-B Microvasc. Res. 69 2005 128 134 (Pubitemid 40724573)
39. S. Yamagishi, T. Matsui, K. Nakamura, and H. Inoue Pigment epithelium-derived factor is a pericyte mitogen secreted by microvascular endothelial cells: possible participation of angiotensin II-elicited PEDF downregulation in diabetic retinopathy Int. J. Tissue React. 27 2005 197 202 (Pubitemid 43056221)
40. H.P. Hammes, S. Martin, K. Federlin, K. Geisen, and M. Brownlee Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy Proc. Natl Acad. Sci. U.S.A. 88 1991 11555 11558 (Pubitemid 21916080)
41. A. Stitt, T.A. Gardiner, N.L. Alderson, P. Canning, N. Frizzell, N. Duffy, C. Boyle, A.S. Januszewski, M. Chachich, J.W. Baynes, and S.R. Thorpe The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes Diabetes 51 2002 2826 2832 (Pubitemid 34970937)
42. R.A. Kowluru, and S. Odenbach Effect of long-term administration of alpha-lipoic acid on retinal capillary cell death and the development of retinopathy in diabetic rats Diabetes 53 2004 3233 3238 (Pubitemid 39564500)
43. H. Liu, J.G. Ren, W.L. Cooper, C.E. Hawkins, M.R. Cowan, and P.Y. Tong Identification of the antivasopermeability effect of pigment epithelium-derived factor and its active site Proc. Natl Acad. Sci. U.S.A. 101 2004 6605 6610 (Pubitemid 38586021)
44. S.X. Zhang, J.J. Wang, G. Gao, K. Parke, and J.X. Ma Pigment epithelium-derived factor downregulates vascular endothelial growth factor (VEGF) expression and inhibits VEGF-VEGF receptor 2 binding in diabetic retinopathy J. Mol. Endocrinol. 37 2006 1 12 (Pubitemid 44288601)
45. S. Yamagishi, R. Abe, Y. Jinnouchi, T. Matsui, T. Imaizumi, and H. Inoue Pigment epithelium-derived factor inhibits vascular endothelial growth factor-induced vascular hyperpermeability both in vitro and in vivo J. Int. Med. Res. 35 2007 896 899 (Pubitemid 350238423)
46. Y. Jinnouchi, S. Yamagishi, T. Matsui, K. Takenaka, Y. Yoshida, K. Nakamura, S. Ueda, and T. Imaizumi Administration of pigment epithelium-derived factor (PEDF) inhibits cold injury-induced brain edema in mice Brain Res. 1167 2007 92 100 (Pubitemid 47302429)
47. H. Funatsu, H. Yamashita, S. Nakamura, T. Mimura, S. Eguchi, H. Noma, and S. Hori Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor are related to diabetic macular edema Ophthalmology 113 2006 294 301 (Pubitemid 43170779)
48. S. Schroder, W. Palinski, and G.W. Schmid-Schonbein Activated monocytes and granulocytes, capillary nonperfusion, and neovascularization in diabetic retinopathy Am. J. Pathol. 139 1991 81 100
49. T.C. Moore, J.E. Moore, Y. Kaji, N. Frizzell, T. Usui, V. Poulaki, I.L. Campbell, A.W. Stitt, T.A. Gardiner, D.B. Archer, and A.P. Adamis The role of advanced glycation end products in retinal microvascular leukostasis Invest Ophthalmol Vis Sci 44 2003 4457 4464 (Pubitemid 37186283)
50. M. Lu, V.L. Perez, N. Ma, K. Miyamoto, H.B. Peng, J.K. Liao, and A.P. Adamis VEGF increases retinal vascular ICAM-1 expression in vivo Invest Ophthalmol Vis Sci 40 1999 1808 1812 (Pubitemid 29297158)
51. S. Yamagishi, T. Matsui, K. Nakamura, H. Inoue, M. Takeuchi, S. Ueda, S. Okuda, and T. Imaizumi Olmesartan blocks inflammatory reactions in endothelial cells evoked by advanced glycation end products by suppressing generation of reactive oxygen species Ophthalmic Res. 40 2008 10 15 (Pubitemid 350308297)
52. Y. Inagaki, S. Yamagishi, T. Okamoto, M. Takeuchi, and S. Amano Pigment epithelium-derived factor prevents advanced glycation end products-induced monocyte chemoattractant protein-1 production in microvascular endothelial cells by suppressing intracellular reactive oxygen species generation Diabetologia 46 2003 284 287 (Pubitemid 36343893)
53. Y. Mitamura, S. Takeuchi, A. Matsuda, Y. Tagawa, Y. Mizue, and J. Nishihira Monocyte chemotactic protein-1 in the vitreous of patients with proliferative diabetic retinopathy Ophthalmologica 215 2001 415 418 (Pubitemid 34008787)
54. S. Yamagishi, S. Ueda, T. Matsui, K. Nakamura, T. Imaizumi, M. Takeuchi, and S. Okuda Pigment epithelium-derived factor (PEDF) prevents advanced glycation end products (AGEs)-elicited endothelial nitric oxide synthase (eNOS) reduction through its anti-oxidative properties Protein Pept. Lett. 14 2007 832 835 (Pubitemid 47416409)
55. S. Yamagishi, T. Matsui, K. Nakamura, M. Takeuchi, and T. Imaizumi Pigment epithelium-derived factor (PEDF) prevents diabetes- or advanced glycation end products (AGE)-elicited retinal leukostasis Microvasc. Res. 72 2006 86 90 (Pubitemid 44118388)
56. S. Yamagishi, T. Matsui, K. Nakamura, T. Yoshida, M. Takeuchi, H. Inoue, Y. Yoshida, and T. Imaizumi Pigment-epithelium-derived factor suppresses expression of receptor for advanced glycation end products in the eye of diabetic rats Ophthalmic Res. 39 2007 92 97 (Pubitemid 46909866)
57. S.X. Zhang, J.J. Wang, G. Gao, C. Shao, R. Mott, and J.X. Ma Pigment epithelium-derived factor (PEDF) is an endogenous antiinflammatory factor FASEB J. 20 2006 323 325 (Pubitemid 46671158)
58. S. Yamagishi, T. Matsui, and H. Inoue Inhibition by advanced glycation end products (AGEs) of pigment epithelium-derived factor (PEDF) gene expression in microvascular endothelial cells Drugs Exp. Clin. Res. 31 2005 227 232 (Pubitemid 43052037)
59. M. Hangaishi, J. Taguchi, T. Miyata, Y. Ikari, M. Togo, Y. Hashimoto, T. Watanabe, S. Kimura, K. Kurokawa, and M. Ohno Increased aggregation of human platelets produced by advanced glycation end products in vitro Biochem. Biophys. Res. Commun. 248 1998 285 292 (Pubitemid 28386414)
60. M. Zoltowska, E. Delvin, E. Ziv, N. Peretti, M. Chartre, and E. Levy Impact of in vivo glycation of LDL on platelet aggregation and monocyte chemotaxis in diabetic psammomys obesus Lipids 39 2004 81 85 (Pubitemid 38296131)
61. S. Yamagishi, H. Fujimori, H. Yonekura, Y. Yamamoto, and H. Yamamoto Advanced glycation endproducts inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells Diabetologia 41 1998 1435 1441 (Pubitemid 28551614)
62. M. Nomura, S. Yamagishi, S. Harada, Y. Hayashi, T. Yamashima, J. Yamashita, and H. Yamamoto Possible participation of autocrine and paracrine vascular endothelial growth factors in hypoxia-induced proliferation of endothelial cells and pericytes J. Biol. Chem. 270 1995 28316 28324
63. S. Yamagishi, T. Kawakami, H. Fujimori, H. Yonekura, N. Tanaka, Y. Yamamoto, H. Urayama, Y. Watanabe, and H. Yamamoto Insulin stimulates the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor Microvasc. Res. 57 1999 329 339 (Pubitemid 29393278)
64. S. Yamagishi, H. Yonekura, Y. Yamamoto, K. Katsuno, F. Sato, I. Mita, H. Ooka, N. Satozawa, T. Kawakami, M. Nomura, and H. Yamamoto Advanced glycation end products-driven angiogenesis in vitro. Induction growth tube formation human microvascular endothelial cells autocrine vascular endothelial growth factor J Biol Chem 272 1997 8723 8730 (Pubitemid 27147841)
65. T. Okamoto, S. Yamagishi, Y. Inagaki, S. Amano, K. Koga, R. Abe, M. Takeuchi, S. Ohno, A. Yoshimura, and Z. Makita Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin FASEB J. 16 2002 1928 1930
66. T. Okamoto, S. Yamagishi, Y. Inagaki, S. Amano, M. Takeuchi, S. Kikuchi, S. Ohno, and A. Yoshimura Incadronate disodium inhibits advanced glycation end products-induced angiogenesis in vitro Biochem. Biophys. Res. Commun. 297 2002 419 424 (Pubitemid 35216188)
67. T. Miyata, C. van Ypersele, Y. de Strihou, K. Ueda, R. Ichimori, H. Inagi, N. Onogi, M. Ishikawa, and K. Kurokawa Nangaku Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms J. Am. Soc. Nephrol. 13 2002 2478 2487
68. S. Yamagishi, T. Matsui, K. Nakamura, H. Inoue, M. Takeuchi, S. Ueda, K. Fukami, S. Okuda, and T. Imaizumi Olmesartan blocks advanced glycation end products (AGEs)-induced angiogenesis in vitro by suppressing receptor for AGEs (RAGE) expression Microvasc. Res. 75 2008 130 134 (Pubitemid 350266734)
69. S. Yamagishi, Y. Inagaki, T. Okamoto, S. Amano, K. Koga, M. Takeuchi, and Z. Makita Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells J. Biol. Chem. 277 2002 20309 20315 (Pubitemid 34967325)
70. S. Yamagishi, K. Fukami, S. Ueda, and S. Okuda Molecular mechanisms of diabetic nephropathy and its therapeutic intervention Curr. Drug Targets 8 2007 952 959
71. A.S. de Vriese, R.G. Tilton, M. Elger, C.C. Stephan, W. Kriz, and N.H. Lameire Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes J. Am. Soc. Nephrol. 12 2001 993 1000 (Pubitemid 32378340)
72. B.F. Schrijvers, A. Flyvbjerg, R.G. Tilton, N.H. Lameire, and A.S. De Vriese A neutralizing VEGF antibody prevents glomerular hypertrophy in a model of obese type 2 diabetes, the Zucker diabetic fatty rat Nephrol. Dial. Transplant. 21 2006 324 329 (Pubitemid 43159984)
73. N.H. Kim, J.H. Oh, J.A. Seo, K.W. Lee, S.G. Kim, K.M. Choi, S.H. Baik, D.S. Choi, Y.S. Kang, S.Y. Han, K.H. Han, Y.H. Ji, and D.R. Cha Vascular endothelial growth factor (VEGF) and soluble VEGF receptor FLT-1 in diabetic nephropathy Kidney Int. 67 2005 167 177 (Pubitemid 40019238)
74. N. Banba, T. Nakamura, M. Matsumura, H. Kuroda, Y. Hattori, and K. Kasai Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy Kidney Int. 58 2000 684 690 (Pubitemid 30620017)
75. F. Chiarelli, F. Cipollone, A. Mohn, M. Marini, A. Iezzi, M. Fazia, S. Tumini, D. De Cesare, M. Pomilio, S.D. Pierdomenico, M. Di Gioacchino, F. Cuccurullo, and A. Mezzetti Circulating monocyte chemoattractant protein-1 and early development of nephropathy in type 1 diabetes Diabetes Care 25 2002 1829 1834 (Pubitemid 41071095)
76. Ishibashi, Y., Matsui, T., Takeuchi, M., Yamagishi, S., Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression, Biochem Biophys Res Commun 391 1405-1408
77. K. Fukami, S. Ueda, S. Yamagishi, S. Kato, Y. Inagaki, M. Takeuchi, Y. Motomiya, R. Bucala, S. Iida, K. Tamaki, T. Imaizumi, M.E. Cooper, and S. Okuda AGEs activate mesangial TGF-beta-Smad signaling via an angiotensin II type I receptor interaction Kidney Int. 66 2004 2137 2147 (Pubitemid 41115277)
78. S. Yamagishi, Y. Inagaki, T. Okamoto, S. Amano, K. Koga, and M. Takeuchi Advanced glycation end products inhibit de novo protein synthesis and induce TGF-beta overexpression in proximal tubular cells Kidney Int. 63 2003 464 473 (Pubitemid 36126793)
79. F.N. Ziyadeh, B.B. Hoffman, D.C. Han, M.C. Iglesias-De La Cruz, S.W. Hong, M. Isono, S. Chen, T.A. McGowan, and K. Sharma Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice Proc. Natl Acad. Sci. U.S.A. 97 2000 8015 8020 (Pubitemid 30460765)
80. D. Suzuki, T. Miyata, N. Saotome, K. Horie, R. Inagi, Y. Yasuda, K. Uchida, Y. Izuhara, M. Yagame, H. Sakai, and K. Kurokawa Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions J. Am. Soc. Nephrol. 10 1999 822 832 (Pubitemid 29149533)
81. C.W. Yang, H. Vlassara, E.P. Peten, C.J. He, G.E. Striker, and L.J. Striker Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease Proc. Natl Acad. Sci. U.S.A. 91 1994 9436 9440 (Pubitemid 24297929)
82. H. Vlassara, L.J. Striker, S. Teichberg, H. Fuh, Y.M. Li, and M. Steffes Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats Proc. Natl Acad. Sci. U.S.A. 91 1994 11704 11708 (Pubitemid 24356413)
83. Y. Yamamoto, I. Kato, T. Doi, H. Yonekura, S. Ohashi, M. Takeuchi, T. Watanabe, S. Yamagishi, S. Sakurai, S. Takasawa, H. Okamoto, and H. Yamamoto Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice J. Clin. Invest. 108 2001 261 268 (Pubitemid 32656250)
84. T.M. Wendt, N. Tanji, J. Guo, T.R. Kislinger, W. Qu, Y. Lu, L.G. Bucciarelli, L.L. Rong, B. Moser, G.S. Markowitz, G. Stein, A. Bierhaus, B. Liliensiek, B. Arnold, P.P. Nawroth, D.M. Stern, V.D. D'Agati, and A.M. Schmidt RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy Am. J. Pathol. 162 2003 1123 1137 (Pubitemid 36350658)
85. N. Reiniger, K. Lau, D. McCalla, B. Eby, B. Cheng, Y. Lu, W. Qu, N. Quadri, R. Ananthakrishnan, M. Furmansky, R. Rosario, F. Song, V. Rai, A. Weinberg, R. Friedman, R. Ramasamy, V. D'Agati,A.M. Schmidt, Deletion of the receptor for advanced glycation end products reduces glomerulosclerosis and preserves renal function in the diabetic OVE26 mouse, Diabetes 59 2043-2054
86. J.M. Forbes, M.E. Cooper, V. Thallas, W.C. Burns, M.C. Thomas, G.C. Brammar, F. Lee, S.L. Grant, L.M. Burrell, G. Jerums, and T.M. Osicka Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy Diabetes 51 2002 3274 3282 (Pubitemid 35246974)
87. M.C. Thomas, C. Tikellis, W.M. Burns, K. Bialkowski, Z. Cao, M.T. Coughlan, K. Jandeleit-Dahm, M.E. Cooper, and J.M. Forbes Interactions between renin angiotensin system and advanced glycation in the kidney J. Am. Soc. Nephrol. 16 2005 2976 2984 (Pubitemid 44743495)
88. T. Matsui, S. Yamagishi, M. Takeuchi, S. Ueda, K. Fukami, S. Okuda, Irbesartan inhibits advanced glycation end product (AGE)-induced proximal tubular cell injury in vitro by suppressing receptor for AGEs (RAGE) expression, Pharmacol Res 61 34-39
89. M. Busch, S. Franke, C. Ruster, G. Wolf, Advanced glycation end-products and the kidney, Eur J Clin Invest 40 742-755
90. Q. Fan, J. Liao, M. Kobayashi, M. Yamashita, L. Gu, T. Gohda, Y. Suzuki, L.N. Wang, S. Horikoshi, and Y. Tomino Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice Nephrol. Dial. Transplant. 19 2004 3012 3020 (Pubitemid 40057622)
91. S. Yamagishi, M. Takeuchi, and H. Inoue Olmesartan medoxomil, a newly developed angiotensin II type 1 receptor antagonist, protects against renal damage in advanced glycation end product (age)-injected rats Drugs Exp. Clin. Res. 31 2005 45 51 (Pubitemid 350056455)
92. K. Sebekova, K. Gazdikova, D. Syrova, P. Blazicek, R. Schinzel, A. Heidland, V. Spustova, and R. Dzurik Effects of ramipril in nondiabetic nephropathy: improved parameters of oxidatives stress and potential modulation of advanced glycation end products J. Hum. Hypertens. 17 2003 265 270 (Pubitemid 36592018)
93. Y. Saisho, N. Komiya, and H. Hirose Effect of valsartan, an angiotensin II receptor blocker, on markers of oxidation and glycation in Japanese type 2 diabetic subjects: blood pressure-independent effect of valsartan Diab. Res. Clin. Pract. 74 2006 201 203 (Pubitemid 44764907)
94. E.J. Lewis, L.G. Hunsicker, W.R. Clarke, T. Berl, M.A. Pohl, J.B. Lewis, E. Ritz, R.C. Atkins, R. Rohde, and I. Raz Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes N. Engl. J. Med. 345 2001 851 860
95. P.C. Chang, T.H. Chen, C.J. Chang, C.C. Hou, P. Chan, and H.M. Lee Advanced glycosylation end products induce inducible nitric oxide synthase (iNOS) expression via a p38 MAPK-dependent pathway Kidney Int. 65 2004 1664 1675 (Pubitemid 38591014)
96. X. Yu, C. Li, X. Li, and L. Cai Rosiglitazone prevents advanced glycation end products-induced renal toxicity likely through suppression of plasminogen activator inhibitor-1 Toxicol. Sci. 96 2007 346 356 (Pubitemid 46432031)
97. S.C. Tang, J.C. Leung, L.Y. Chan, A.W. Tsang, and K.N. Lai Activation of tubular epithelial cells in diabetic nephropathy and the role of the peroxisome proliferator-activated receptor-gamma agonist J. Am. Soc. Nephrol. 17 2006 1633 1643 (Pubitemid 43794666)
98. N. Marx, D. Walcher, N. Ivanova, K. Rautzenberg, A. Jung, R. Friedl, V. Hombach, R. de Caterina, G. Basta, M.P. Wautier, and J.L. Wautiers Thiazolidinediones reduce endothelial expression of receptors for advanced glycation end products Diabetes 53 2004 2662 2668 (Pubitemid 39299276)
99. L. Wang, F.D. Cui, and H. Sunada Preparation and evaluation of solid dispersions of nitrendipine prepared with fine silica particles using the melt-mixing method Chem Pharm Bull Tokyo 54 2006 37 43 (Pubitemid 43036746)
100. S. Yamagishi, T. Matsui, K. Nakamura, M. Takeuchi, and H. Inoue Telmisartan inhibits advanced glycation end products (AGEs)-elicited endothelial cell injury by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gamma activation Protein Pept. Lett. 15 2008 850 853
101. T. Matsui, K. Nakamura, M. Takeuchi, and S. Yamagishi Telmisartan blocks advanced glycation end-product (AGE)-induced plasminogen activator inhibitor-1 gene expression in endothelial cells through activation of peroxisome proliferator-activated receptor-g Lett Drug Des Dis 5 2008 477 480
102. T. Matsui, S. Yamagishi, S. Ueda, K. Nakamura, T. Imaizumi, M. Takeuchi, and H. Inoue Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-induced monocyte chemoattractant protein-1 expression in mesangial cells through downregulation of receptor for AGEs via peroxisome proliferator-activated receptor-gamma activation J. Int. Med. Res. 35 2007 482 489 (Pubitemid 47261110)
103. T. Yoshida, S. Yamagishi, K. Nakamura, T. Matsui, T. Imaizumi, M. Takeuchi, H. Koga, T. Ueno, and M. Sata Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation Diabetologia 49 2006 3094 3099 (Pubitemid 44730314)
104. T. Yoshida, S. Yamagishi, T. Matsui, K. Nakamura, T. Ueno, M. Takeuchi, and M. Sata Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-elicited hepatic insulin resistance via peroxisome proliferator-activated receptor-gamma activation J. Int. Med. Res. 36 2008 237 243 (Pubitemid 351516604)
105. L. Ma, H.Q. Gao, B.Y. Li, Y.B. Ma, B.A. You, and F.L. Zhang Grape seed proanthocyanidin extracts inhibit vascular cell adhesion molecule expression induced by advanced glycation end products through activation of peroxisome proliferators-activated receptor gamma J. Cardiovasc. Pharmacol. 49 2007 293 298 (Pubitemid 46855123)
106. T. Matsui, S. Yamagishi, M. Takeuchi, S. Ueda, K. Fukami, and S. Okuda Nifedipine, a calcium channel blocker, inhibits advanced glycation end product (AGE)-elicited mesangial cell damage by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gamma activation Biochem. Biophys. Res. Commun. 385 2009 269 272
107. J.J. Wang, S.X. Zhang, K. Lu, Y. Chen, R. Mott, S. Sato, and J.X. Ma Decreased expression of pigment epithelium-derived factor is involved in the pathogenesis of diabetic nephropathy Diabetes 54 2005 243 250 (Pubitemid 40105119)
108. J.J. Wang, S.X. Zhang, R. Mott, R.R. Knapp, W. Cao, K. Lau, and J.X. Ma Salutary effect of pigment epithelium-derived factor in diabetic nephropathy: evidence for antifibrogenic activities Diabetes 55 2006 1678 1685 (Pubitemid 44324120)
109. S. Maeda, T. Matsui, M. Takeuchi, Y. Yoshida, R. Yamakawa, K. Fukami, and S.-I. Yamagishi Pigment epithelium-derived factor (PEDF) inhibits proximal tubular cell injury in early diabetic nephropathy by suppressing advanced glycation end products (AGEs)-receptor (RAGE) axis Pharmacol. Res. 63 2011 241 248
110. T.C. Ho, S.L. Chen, Y.C. Yang, C.L. Liao, H.C. Cheng, and Y.P. Tsao PEDF induces p53-mediated apoptosis through PPAR gamma signaling in human umbilical vein endothelial cells Cardiovasc. Res. 76 2007 213 223
111. T.C. Ho, Y.C. Yang, S.L. Chen, P.C. Kuo, H.K. Sytwu, H.C. Cheng, and Y.P. Tsao Pigment epithelium-derived factor induces THP-1 macrophage apoptosis and necrosis by the induction of the peroxisome proliferator-activated receptor gamma Mol. Immunol. 45 2008 898 909
112. W.K. Bolton, D.C. Cattran, M.E. Williams, S.G. Adler, G.B. Appel, K. Cartwright, P.G. Foiles, B.I. Freedman, P. Raskin, R.E. Ratner, B.S. Spinowitz, F.C. Whittier, and J.P. Wuerth Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy Am. J. Nephrol. 24 2004 32 40 (Pubitemid 38250484)
113. R. Bucala, K.J. Tracey, and A. Cerami Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes J. Clin. Invest. 87 1991 432 438
114. R. Bucala, R. Mitchell, K. Arnold, T. Innerarity, H. Vlassara, and A. Cerami Identification of the major site of apolipoprotein B modification by advanced glycosylation end products blocking uptake by the low density lipoprotein receptor J. Biol. Chem. 270 1995 10828 10832
115. M.R. Hoenig, C. Bianchi, A. Rosenzweig, and F.W. Sellke Decreased vascular repair and neovascularization with ageing: mechanisms and clinical relevance with an emphasis on hypoxia-inducible factor-1 Curr. Mol. Med. 8 2008 754 767
116. Q. Chen, L. Dong, L. Wang, L. Kang, and B. Xu Advanced glycation end products impair function of late endothelial progenitor cells through effects on protein kinase Akt and cyclooxygenase-2 Biochem. Biophys. Res. Commun. 381 2009 192 197
117. R.J. Scheubel, S. Kahrstedt, H. Weber, J. Holtz, I. Friedrich, J. Borgermann, R.E. Silber, and A. Simm Depression of progenitor cell function by advanced glycation endproducts (AGEs): potential relevance for impaired angiogenesis in advanced age and diabetes Exp. Gerontol. 41 2006 540 548 (Pubitemid 43765896)
118. A.D. Bhatwadekar, J.V. Glenn, G. Li, T.M. Curtis, T.A. Gardiner, and A.W. Stitt Advanced glycation of fibronectin impairs vascular repair by endothelial progenitor cells: implications for vasodegeneration in diabetic retinopathy Invest Ophthalmol Vis Sci 49 2008 1232 1241
119. J. Chen, L. Huang, M. Song, S. Yu, P. Gao, and J. Jing C-reactive protein upregulates receptor for advanced glycation end products expression and alters antioxidant defenses in rat endothelial progenitor cells J. Cardiovasc. Pharmacol. 53 2009 359 367
120. T. Murohara, T. Asahara, M. Silver, C. Bauters, H. Masuda, C. Kalka, M. Kearney, D. Chen, J.F. Symes, M.C. Fishman, P.L. Huang, and J.M. Isner Nitric oxide synthase modulates angiogenesis in response to tissue ischemia J. Clin. Invest. 101 1998 2567 2578 (Pubitemid 28270451)
121. H. Ueno, H. Koyama, S. Fukumoto, S. Tanaka, T. Shoji, T. Shoji, M. Emoto, H. Tahara, M. Inaba, R. Kakiya, T. Tabata, T. Miyata,Y. Nishizawa, Advanced glycation end products, carotid atherosclerosis, and circulating endothelial progenitor cells in patients with end-stage renal disease, Metabolism.
122. S. Yamagishi, H. Fujimori, H. Yonekura, N. Tanaka, and H. Yamamoto Advanced glycation endproducts accelerate calcification in microvascular pericytes Biochem. Biophys. Res. Commun. 258 1999 353 357 (Pubitemid 29287055)
123. S.S. Shaw, A.M. Schmidt, A.K. Banes, X. Wang, D.M. Stern, and M.B. Marrero S100B-RAGE-mediated augmentation of angiotensin II-induced activation of JAK2 in vascular smooth muscle cells is dependent on PLD2 Diabetes 52 2003 2381 2388 (Pubitemid 37059510)
124. T. Sakaguchi, S.F. Yan, S.D. Yan, D. Belov, L.L. Rong, M. Sousa, M. Andrassy, S.P. Marso, S. Duda, B. Arnold, B. Liliensiek, P.P. Nawroth, D.M. Stern, A.M. Schmidt, and Y. Naka Central role of RAGE-dependent neointimal expansion in arterial restenosis J. Clin. Invest. 111 2003 959 972 (Pubitemid 36397472)
125. A. Soro-Paavonen, A.M. Watson, J. Li, K. Paavonen, A. Koitka, A.C. Calkin, D. Barit, M.T. Coughlan, B.G. Drew, G.I. Lancaster, M. Thomas, J.M. Forbes, P.P. Nawroth, A. Bierhaus, M.E. Cooper, and K.A. Jandeleit-Dahm Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes Diabetes 57 2008 2461 2469
126. K. Asanuma, and P. Mundel The role of podocytes in glomerular pathobiology Clin. Exp. Nephrol. 7 2003 255 259 (Pubitemid 38031285)